Shockwave Medical, Inc. (NASDAQ:SWAV) Director Frank T. Watkins Sells 2,000 Shares

Shockwave Medical, Inc. (NASDAQ:SWAVGet Free Report) Director Frank T. Watkins sold 2,000 shares of the stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $231.76, for a total value of $463,520.00. Following the completion of the sale, the director now owns 4,532 shares in the company, valued at approximately $1,050,336.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shockwave Medical Price Performance

Shares of NASDAQ SWAV opened at $233.71 on Friday. The company has a debt-to-equity ratio of 1.22, a quick ratio of 13.19 and a current ratio of 14.43. The company has a market cap of $8.62 billion, a PE ratio of 36.40, a P/E/G ratio of 10.15 and a beta of 0.88. The business has a 50-day simple moving average of $205.15 and a two-hundred day simple moving average of $207.30. Shockwave Medical, Inc. has a fifty-two week low of $157.00 and a fifty-two week high of $315.95.

Institutional Investors Weigh In On Shockwave Medical

Institutional investors have recently added to or reduced their stakes in the business. Lindbrook Capital LLC boosted its holdings in Shockwave Medical by 64.8% in the third quarter. Lindbrook Capital LLC now owns 150 shares of the company’s stock worth $30,000 after acquiring an additional 59 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Shockwave Medical by 297.4% in the third quarter. EverSource Wealth Advisors LLC now owns 155 shares of the company’s stock worth $31,000 after acquiring an additional 116 shares in the last quarter. Asset Management One Co. Ltd. purchased a new position in shares of Shockwave Medical in the fourth quarter worth about $34,000. Nemes Rush Group LLC purchased a new position in shares of Shockwave Medical in the second quarter worth about $39,000. Finally, Quest Partners LLC purchased a new position in shares of Shockwave Medical in the fourth quarter worth about $41,000. Institutional investors and hedge funds own 87.35% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on SWAV. Morgan Stanley cut their price target on Shockwave Medical from $284.00 to $223.00 and set an “overweight” rating on the stock in a research note on Monday, December 4th. Needham & Company LLC cut their price target on Shockwave Medical from $265.00 to $260.00 and set a “buy” rating on the stock in a research note on Tuesday, November 7th. SVB Leerink initiated coverage on Shockwave Medical in a research report on Monday, October 16th. They set an “outperform” rating and a $263.00 price objective on the stock. Finally, Leerink Partnrs reaffirmed an “outperform” rating on shares of Shockwave Medical in a research report on Monday, October 16th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Shockwave Medical currently has an average rating of “Moderate Buy” and an average price target of $263.00.

View Our Latest Stock Report on Shockwave Medical

Shockwave Medical Company Profile

(Get Free Report)

ShockWave Medical, Inc, a medical device company, develops intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters for use in our IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter for use in IVL System in large diameter vessels.

Featured Articles

Insider Buying and Selling by Quarter for Shockwave Medical (NASDAQ:SWAV)

Receive News & Ratings for Shockwave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shockwave Medical and related companies with MarketBeat.com's FREE daily email newsletter.